New combo therapy aims to shrink Hard-to-Treat tumors

NCT ID NCT07095868

Recruiting now Disease control Sponsor: Everest Medicines (Beijing) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. About 94 participants will be enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SELECTED TYPES OF SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SELECTED TYPES OF SOLID TUMOR

Contacts and locations

Locations

Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410006, China
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10022, United States
NEXT Oncology
RECRUITING

Fairfax, Virginia, 22031, United States
Nanjing Drum Tower Hospital
RECRUITING

Nanjing, Jiangsu, 210000, China
Shanghai Pulmonary Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200433, China
The First Affiliated Hospital With Nanjing Medical University
RECRUITING

Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.